Bayer AKT1/2 allosteric inhibitor (experimental)

· Bayer

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Bayer AKT1/2 allosteric inhibitor (experimental), covering 2016-12-28 to 2016-12-28. Get the full timeline:

Most recent: Clinical Trial Update: Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients [Phase 1]